For instance, previous studies establishing the treatment standards for glioblastoma (CNS WHO grade 4) as well as isocitrate dehydrogenase (IDH)-mutant glioma (astrocytoma and oligodendroglioma) did not address in full detail the now established insights on molecular markers in the diagnostic workup [13–16]. This evidence concerns the gene IDH1 and glioblastoma.